DOCSLIB.ORG

A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer1 2056 Vol. 9, 2056–2065, June 2003 Clinical Cancer Research A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer1 Dishan H. Gunawardana,2 Russell L. Basser, genitor cells increased in response to rhLIF. In stage 2, Ian D. Davis, Jonathan Cebon, Paul Mitchell, platelet recovery to baseline levels was earlier for patients ؍ ␮ < Craig Underhill, Trevor J. Kilpatrick, receiving higher doses of rhLIF ( 4.0 g/kg/day; P 0.02). The neutrophil nadir after chemotherapy was less severe in Katrina Reardon, Michael D. Green, Peter Bardy, patients receiving >4.0 ␮g/kg/day of rhLIF. In stages 1 and Pene Amor, David Crump, Siobhan Ng, 2, increases in C reactive protein were seen at higher doses. Roger L. Nation, and C. Glenn Begley Several patients developed evidence of autonomic dysfunc- Centre for Developmental Cancer Therapeutics,3 Parkville, Victoria tion, in particular impotence and episodic hypotension. The 3050 [D. H. G., R. L. B., I. D. D., J. C., P. M., C. U., T. J. K., K. R., dose-limiting toxicities were hypotension and rigors. Phar- M. D. G., S. N.]; Department of Hematology, Institute of Medical and macokinetic studies demonstrated a short half-life (1–5 h) Veterinary Science, Adelaide, South Australia [P. B.]; Amrad Operations, Richmond, Victoria, Australia [P. A., D. C.]; Centre for independent of dose. Pharmaceutical Research, University of South Australia, North Conclusions: We demonstrated a biological effect of Terrace, Adelaide, South Australia [R. L. N.]; and Centre for Child rhLIF on blood progenitor cells, C reactive protein levels, Health Research, University of Western Australia, TVW Telethon and hemopoietic recovery after chemotherapy. Institute for Child Health Research and Western Australian Institute for Medical Research, West Perth, Western Australia [C. G. B.] INTRODUCTION ABSTRACT LIF4 is a cytokine with a broad range of in vitro and Purpose: Leukemia inhibitory factor (LIF) is a pleio- in vivo biological effects. The molecule was first described as tropic molecule of the interleukin 6 family of cytokines. We an inducer of monocytic differentiation in the leukemic cell aimed to examine the safety, pharmacokinetics, and biolog- line M1 (1, 2). LIF is a member of a cytokine family that also ical effects of recombinant human LIF (rhLIF, emfilermin) includes IL-6, IL-11, oncostatin M, ciliary neurotrophic fac- in patients with advanced cancer. tor, and cardiotrophin 1. These cytokines have overlapping Experimental Design: In stage 1 of the study, 34 patients biological activities and act through receptors that share a received rhLIF or placebo (3:1 ratio) at doses of 0.25–16.0 common signaling molecule, the gp130 subunit (3). The other ␮g/kg/day or 4.0 ␮g/kg three times daily for 7 days. In stage subunit of the LIFR complex is the LIFR␤ chain. Expression 2, 40 patients received rhLIF or placebo, either once daily of LIFR␤ determines which cells respond to LIF, because for 14 days commencing the day after chemotherapy (0.25– gp130 is expressed ubiquitously (4). Ligand binding to the 8.0 ␮g/kg/day) or for 7 days commencing the day before receptor complex results in activation of intracellular signal- chemotherapy (4.0 ␮g/kg three times daily). The chemother- ing via the Janus-activated kinase/signal transducers and apy was cisplatin 75 mg/m2 and paclitaxel 135 mg/m2. activators of transcription pathway. Results: In stage 1, platelet counts increased in most Receptors for LIF are expressed on hemopoietic cells patients, including those who received placebo. Blood pro- (macrophages and megakaryocytes), hepatocytes, osteoblasts, preadipocytes, embryonic stem cells, myoblasts, and neuronal cells (5, 6). However, the in vitro biological effects of LIF vary depending on the cell type, so that for example LIF stimulates Received 3/21/02; revised 1/3/03; accepted 1/7/03. differentiation in M1 cells and inhibits differentiation in embry- The costs of publication of this article were defrayed in part by the onic stem cells. In vivo studies in mice have shown that LIF payment of page charges. This article must therefore be hereby marked produces a 2-fold increase in bone marrow megakaryocytes with advertisement in accordance with 18 U.S.C. Section 1734 solely to a dose-dependent increase in platelet numbers (7). Increased indicate this fact. 1 Supported in part by Amrad Operations and the National Health and Medical Research Council, Canberra. P. A. and D. C. were employed by Amrad Operations, whose potential product was studied in the present work. 2 To whom requests for reprints should be addressed, at Department of 4 The abbreviations used are: LIF, leukemia inhibitory factor; IL, inter- Hematology and Medical Oncology, Royal Melbourne Hospital, leukin; LIFR, leukemia inhibitory factor receptor; rh, recombinant hu- Parkville, Victoria 3050, Australia. Phone: 613-9342-7695; Fax: 613- man; ECOG, Eastern Cooperative Oncology Group; tds, three times 9347-7508; E-mail: [email protected]. daily; Epo, erythropoietin; ESR, erythrocyte sedimentation rate; PBPC, 3 Affiliated with: Ludwig Institute Oncology Unit, Austin Repatriation peripheral blood progenitor/stem cell; GM-CFC, granulocyte-macroph- Medical Centre, Heidelberg, Victoria; the Department of Hematology age colony-forming cell; G-CSF, granulocyte colony-stimulating factor; and Medical Oncology, Rotary Bone Marrow Research Laboratories, GM-CSF, granulocyte macrophage colony-stimulating factor; SCF, Royal Melbourne Hospital, Parkville, Victoria, Australia; Walter and stem cell factor; Meg-CFC, megakaryocyte colony-forming cell; Cmax, Eliza Hall Institute for Medical Research, Parkville, Victoria, Australia; maximum concentration; AUC, area under the plasma concentration- and the Department of Hematology and Medical Oncology, Western time curve; Cl, clearance; Vd, volume of distribution; t1/2, half-life; Hospital, Footscray, Victoria, Australia. BFU-E, blast-forming unit (erythroid). Downloaded from clincancerres.aacrjournals.org on October 2, 2021. © 2003 American Association for Cancer Research. Clinical Cancer Research 2057 platelet levels have also been observed in primates (8). The action of LIF on nerve cells has also been examined in animal models. Direct application of LIF to sites of nerve transection improved survival of both sensory and motor neurons (9, 10). Nerve transection has been shown to increase expression of LIF and IL-6, and is associated with retrograde axonal transport of LIF (11). LIF has also been shown to retard progression of motor neuron disease in a murine model of this disorder (12). Other biological effects of LIF include induction of acute phase proteins (8), reduced lipoprotein lipase activity, and os- teoblast stimulation (13). Emfilermin is rhLIF produced in Escherichia coli. Admin- Fig. 1 Protocol schema. In stage 1, patients were randomized to re- istration of a single s.c. dose in healthy volunteers found that ceive rhLIF or placebo in a 3:1 ratio, which drug was then administered rhLIF was safe and well tolerated up to doses of 4 ␮g/kg.5 for 7 days. This was followed by a period of at least 7 days and maximum of 28 days observation. Stage 2 consisted of chemotherapy Here we report results of a randomized, blinded, placebo- that, in the majority of patients, was followed by study drug adminis- controlled, Phase I dose escalation study to test the safety and tered daily for 14 days. One cohort of patients (4.0 ␮g/kg tds rhLIF) pharmacokinetics of rhLIF administered before and after chem- received study drug from the day before chemotherapy and for a total of otherapy in patients with advanced cancer. 7 days. PATIENTS AND METHODS Patients. Eligible patients were those with advanced can- ␮ cer at least 18 years of age, ECOG performance status of 0–2, the 4.0 g/kg tds cohort. Patients continuing from stage 1 to absolute neutrophil count of Ն1.5 ϫ 109/liter, hemoglobin level stage 2 remained on the same dose of rhLIF, with the exception ␮ of Ն90 g/liter, and platelet count of 120–500 ϫ 109/liter. that patients who received 16.0 g/kg/day in stage 1 were given Ն 8.0 ␮g/kg/day in stage 2. Adequate renal (creatinine Cl 1.2 ml/sec) and hepatic (biliru- 2 Յ ␮ Chemotherapy consisted of paclitaxel 135 mg/m given bin 25 mol/liter) function were also required. Exclusion 2 criteria included surgery, radiotherapy, or chemotherapy within over3hbyi.v. infusion, followed by cisplatin 75 mg/m i.v. 4 weeks of study entry, prior irradiation to Ͼ30% of estimated over 1 h, with mannitol 10% i.v. over 15 min. Premedication for red marrow volume, and uncontrolled brain metastases. chemotherapy was 20 mg of dexamethasone given p.o. the night The study was approved by the Institutional Ethics Com- before chemotherapy and again on the morning of chemother- mittees of the participating hospitals. Each patient gave in- apy, 50 mg ranitidine i.v., 12.5 mg promethazine i.v. or equiv- formed consent before treatment. alent, and 24 mg ondansetron i.v. The study drug was commenced the day after chemother- Study Design apy for patients in the once daily cohorts and given for a total of 14 days. Patients receiving 4.0 ␮g/kg tds began treatment with The study design is shown in Fig. 1. rhLIF or placebo the day before chemotherapy, and continued Stage 1. The study was double-blinded with respect to for a total of 7 days. Study involvement was completed after one rhLIF (emfilermin is the International Nonproprietary Name cycle of chemotherapy, but patients were able to receive addi- issued by the WHO for rhLIF produced in E. coli). Patients were tional chemotherapy cycles (but without rhLIF) at the discretion randomized to rhLIF or placebo in a 3:1 ratio. A computerized of the investigator. During the study, the use of cytokines other randomization schedule was used. Patients received study drug than rhLIF such as filgrastim, sargramostim, or Epo was not alone given s.c.
Load more

Recommended publications
  • Therapeutic Class Overview Colony Stimulating Factors
    Therapeutic Class Overview Colony Stimulating Factors Therapeutic Class Overview/Summary: This review will focus on the granulocyte colony stimulating factors (G-CSFs) and granulocyte- macrophage colony stimulating factors (GM-CSFs).1-5 Colony-stimulating factors (CSFs) fall under the naturally occurring glycoprotein cytokines, one of the main groups of immunomodulators.6 In general, these proteins are vital to the proliferation and differentiation of hematopoietic progenitor cells.6-8 The G- CSFs commercially available in the United States include pegfilgrastim (Neulasta®), filgrastim (Neupogen®), filgrastim-sndz (Zarxio®), and tbo-filgrastim (Granix®). While filgrastim-sndz and tbo- filgrastim are the same recombinant human G-CSF as filgrastim, only filgrastim-sndz is considered a biosimilar drug as it was approved through the biosimilar pathway. At the time tbo-filgrastim was approved, a regulatory pathway for biosimilar drugs had not yet been established in the United States and tbo-filgrastim was filed under its own Biologic License Application.9 Only one GM-CSF is currently available, sargramostim (Leukine). These agents are Food and Drug Administration (FDA)-approved for a variety of conditions relating to neutropenia or for the collection of hematopoietic progenitor cells for collection by leukapheresis.1-5 Due to the pathway taken, tbo-filgrastim does not share all of the same indications as filgrastim and these two products are not interchangeable. It is important to note that although filgrastim-sndz is a biosimilar product, and it was approved with all the same indications as filgrastim at the time, filgrastim has since received FDA-approval for an additional indication that filgrastim-sndz does not have, to increase survival in patients with acute exposure to myelosuppressive doses of radiation.1-3A complete list of indications for each agent can be found in Table 1.
    [Show full text]
  • Sargramostim (Leukine®)
    Policy Medical Policy Manual Approved Revision: Do Not Implement until 8/31/21 Sargramostim (Leukine®) NDC CODE(S) 71837-5843-XX LEUKINE 250MCG Solution Reconstituted (PARTNER THERAPEUTICS) DESCRIPTION Sargramostim is a recombinant human granulocyte-macrophage colony stimulating factor (rGM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. Like endogenous GM-CSF, rGM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells in the granulocyte-macrophage pathways which include neutrophils, monocytes/macrophages and myeloid-derived dendritic cells. It is also capable of activating mature granulocytes and macrophages. Various cellular responses such as division, maturation and activation are induced by GM-CSF binding to specific receptors expressed on the cell surface of target cells. POLICY Sargramostim for the treatment of the following is considered medically necessary: o Acute myelogenous leukemia following induction or consolidation chemotherapy o Bone Marrow Transplantation (BMT) failure or Engraftment Delay o Individuals acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome [H-ARS]) o Myeloid reconstitution after autologous or allogeneic bone marrow transplant (BMT) o Peripheral Blood Progenitor Cell (PBPC) mobilization and transplant Sargramostim for the treatment of chemotherapy-induced febrile neutropenia is considered medically necessary if the medical appropriateness
    [Show full text]
  • Comparison Between Filgrastim and Lenograstim Plus Chemotherapy For
    Bone Marrow Transplantation (2010) 45, 277–281 & 2010 Macmillan Publishers Limited All rights reserved 0268-3369/10 $32.00 www.nature.com/bmt ORIGINAL ARTICLE Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs R Ria, T Gasparre, G Mangialardi, A Bruno, G Iodice, A Vacca and F Dammacco Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy Recombinant human (rHu) G-CSF has been widely used during transplantation.4 However, the use of G-CSF after to treat neutropenia and mobilize PBPCs for their autologous PBPC transplantation has been queried, as its autologous and allogeneic transplantation. It shortens further reduction in time to a safe neutrophil count5,6 does neutropenia and thus reduces the frequency of neutropenic not always imply fewer significant clinical events, such as fever. We compared the efficiency of glycosylated rHu infections, length of hospitalization, extrahematological and non-glycosylated Hu G-CSF in mobilizing hemato- toxicities or mortality.7,8 Even so, the ASCO guidelines still poietic progenitor cells (HPCs). In total, 86 patients were recommend the use of growth factors after autologous consecutively enrolled for mobilization with CY plus either PBPC transplantation.9 glycosylated or non-glycosylated G-CSF, and under- G-CSF induces the proliferation and differentiation of went leukapheresis. The HPC content of each collection, myeloid precursor cells, and also provides a functional toxicity, days of leukapheresis needed to reach the activity that influences chemotaxis, respiratory burst and minimum HPC target and days to recover WBC (X500 Ag expression of neutrophils.
    [Show full text]
  • Regenerative Mechanisms and Novel Therapeutic Approaches
    brain sciences Review Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches Rashad Hussain 1,*, Hira Zubair 2, Sarah Pursell 1 and Muhammad Shahab 2,* 1 Center for Translational Neuromedicine, University of Rochester, NY 14642, USA; [email protected] 2 Department of Animal Sciences, Quaid-i-Azam University, Islamabad 45320, Pakistan; [email protected] * Correspondence: [email protected] (R.H.); [email protected] (M.S.); Tel.: +1-585-276-6390 (R.H.); +92-51-9064-3014 (M.S.) Received: 13 July 2018; Accepted: 12 September 2018; Published: 15 September 2018 Abstract: Regeneration refers to regrowth of tissue in the central nervous system. It includes generation of new neurons, glia, myelin, and synapses, as well as the regaining of essential functions: sensory, motor, emotional and cognitive abilities. Unfortunately, regeneration within the nervous system is very slow compared to other body systems. This relative slowness is attributed to increased vulnerability to irreversible cellular insults and the loss of function due to the very long lifespan of neurons, the stretch of cells and cytoplasm over several dozens of inches throughout the body, insufficiency of the tissue-level waste removal system, and minimal neural cell proliferation/self-renewal capacity. In this context, the current review summarized the most common features of major neurodegenerative disorders; their causes and consequences and proposed novel therapeutic approaches. Keywords: neuroregeneration; mechanisms; therapeutics; neurogenesis; intra-cellular signaling 1. Introduction Regeneration processes within the nervous system are referred to as neuroregeneration. It includes, but is not limited to, the generation of new neurons, axons, glia, and synapses. It was not considered possible until a couple of decades ago, when the discovery of neural precursor cells in the sub-ventricular zone (SVZ) and other regions shattered the dogma [1–4].
    [Show full text]
  • G-CSF Protects Motoneurons Against Axotomy-Induced Apoptotic Death In
    Henriques et al. BMC Neuroscience 2010, 11:25 http://www.biomedcentral.com/1471-2202/11/25 RESEARCH ARTICLE Open Access G-CSF protects motoneurons against axotomy- induced apoptotic death in neonatal mice Alexandre Henriques1,2,3, Claudia Pitzer1*, Luc Dupuis2,3, Armin Schneider1* Abstract Background: Granulocyte colony stimulating factor (G-CSF) is a growth factor essential for generation of neutrophilic granulocytes. Apart from this hematopoietic function, we have recently uncovered potent neuroprotective and regenerative properties of G-CSF in the central nervous system (CNS). The G-CSF receptor and G-CSF itself are expressed in a motoneurons, G-CSF protects motoneurons, and improves outcome in the SOD1(G93A) transgenic mouse model for amyotrophic lateral sclerosis (ALS). In vitro, G-CSF acts anti- apoptotically on motoneuronal cells. Due to the pleiotrophic effects of G-CSF and the complexity of the SOD1 transgenic ALS models it was however not possible to clearly distinguish between directly mediated anti- apoptotic and indirectly protective effects on motoneurons. Here we studied whether G-CSF is able to protect motoneurons from purely apoptotic cell death induced by a monocausal paradigm, neonatal sciatic nerve axotomy. Results: We performed sciatic nerve axotomy in neonatal mice overexpressing G-CSF in the CNS and found that G-CSF transgenic mice displayed significantly higher numbers of surviving lumbar motoneurons 4 days following axotomy than their littermate controls. Also, surviving motoneurons in G-CSF overexpressing animals were larger, suggesting additional trophic effects of this growth factor. Conclusions: In this model of pure apoptotic cell death the protective effects of G-CSF indicate direct actions of G-CSF on motoneurons in vivo.
    [Show full text]
  • ©Ferrata Storti Foundation
    Stem Cell Transplantation • Research Paper Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors Frank Kroschinsky Background and Objectives. Short-term treatment with granulocyte colony-stimulating Kristina Hölig factor (G-CSF) has been established as the standard regimen for mobilizing allogeneic Kirsten Poppe-Thiede peripheral blood progenitor cells (PBPC) from healthy donors. The pegylated form of fil- Kristin Zimmer grastim (pegfilgrastim) has a longer elimination half-life because of decreased serum Rainer Ordemann clearance and might be a convenient alternative for stem cell mobilization. Matthias Blechschmidt Uta Oelschlaegel Design and Methods. Twenty-five family (n=15) or unrelated (n=10) healthy donors received a single-dose of 12 mg pegfilgrastim for mobilization of allogeneic PBPC. Martin Bornhauser + Gabi Rall Donors with inadequate mobilization (blood CD34 cells ≤5/µL on day 3 or ≤20/µL on Claudia Rutt day 4) were given additional daily doses of 10 µg/kg conventional filgrastim. Gerhard Ehninger Leukapheresis was planned to start on day 5. Results. All harvests were completed successfully. In 20 out of 25 donors (80 %) only a single apheresis was necessary. Additional non-pegylated filgrastim had to be given to only one 74-year old family donor. The maximum concentration of circulating CD34+ + cells occurred on day 5 (median 67/µL, range 10-385/µL). The median yield of CD34 cells was 9.3 (range 3.2-39.1) 106/kg of the recipient´s body weight. The median × 8 number of T cells in the apheresis products was 3.9 (range 2.7-10.8)×10 /kg.
    [Show full text]
  • Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Coding Implications Last Review Date: 10/16 Revision Log
    Clinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Coding Implications Last Review Date: 10/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for sargramostim (Leukine® injection, for subcutaneous or intravenous use). Policy/Criteria It is the policy of health plans affiliated with Centene Corporation® that Leukine is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Acute Myeloid Leukemia (must meet all): 1. Leukine is prescribed for use following induction therapy for acute myeloid leukemia (AML); 2. Member has none of the following contraindications: a. Excessive leukemic myeloid blasts in the bone marrow/peripheral blood (≥ 10%); b. Known hypersensitivity to granulocyte-macrophage colony stimulating factor (GM-CSF), yeast-derived products or any component of the product; c. Concomitant use with chemotherapy/radiotherapy. Approval duration: 6 months B. Peripheral Blood Progenitor Cell Collection and Transplantation (must meet all): 1. Leukine is prescribed for either of the following: a. Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis in anticipation of transplantation after myeloablative chemotherapy; b. Following myeloablative chemotherapy and transplantation of autologous hematopoietic progenitor cells; 2. Member has none of the following contraindications: a. Excessive leukemic myeloid blasts in the bone marrow/ peripheral blood (≥ 10%); b. Known hypersensitivity to GM-CSF, yeast-derived products or any component of the product; c. Concomitant use with chemotherapy/radiotherapy. Approval duration: 6 months C.
    [Show full text]
  • NEUPOGEN® (Filgrastim) DESCRIPTION Filgrastim Is a Human Granulocyte Colony-Stimulating Factor (G-CSF)‚ Produced by Recombinant DNA Technology
    NEUPOGEN® (Filgrastim) DESCRIPTION Filgrastim is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. NEUPOGEN® is the Amgen Inc. trademark for filgrastim‚ which has been selected as the name for recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF). NEUPOGEN® is a 175 amino acid protein manufactured by recombinant DNA technology.1 NEUPOGEN® is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. NEUPOGEN® has a molecular weight of 18‚800 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because NEUPOGEN® is produced in E coli‚ the product is nonglycosylated and thus differs from G-CSF isolated from a human cell. NEUPOGEN is a sterile‚ clear‚ colorless‚ preservative-free liquid for parenteral administration containing filgrastim at a specific activity of 1.0 ± 0.6 x 108 U/mg (as measured by a cell mitogenesis assay). The product is available in single-use vials and prefilled syringes. The single-use vials contain either 300 mcg or 480 mcg filgrastim at a fill volume of 1.0 mL or 1.6 mL, respectively. The single-use prefilled syringes contain either 300 mcg or 480 mcg filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. See table below for product composition of each single-use vial or prefilled syringe. 300 mcg/ 480 mcg/ 300 mcg/ 480 mcg/ 1.0 mL Vial 1.6 mL Vial 0.5 mL Syringe 0.8 mL Syringe filgrastim 300 mcg 480 mcg 300 mcg 480 mcg Acetate 0.59 mg 0.94 mg 0.295 mg 0.472 mg Sorbitol 50.0 mg 80.0 mg 25.0 mg 40.0 mg Polysorbate 80 0.04 mg 0.064 mg 0.02 mg 0.032 mg Sodium 0.035 mg 0.056 mg 0.0175 mg 0.028 mg Water for Injection USP q.s.
    [Show full text]
  • Autoimmune Pulmonary Alveolar Proteinosis in an Adolescent Successfully Treated with Inhaled Rhgm-CSF
    Respiratory Medicine Case Reports 23 (2018) 167–169 Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr Case report Autoimmune pulmonary alveolar proteinosis in an adolescent successfully T treated with inhaled rhGM-CSF (molgramostim) ∗ Marta E. Gajewskaa, , Sajitha S. Sritharana, Eric Santoni-Rugiub, Elisabeth M. Bendstrupa a Department of Respiratory Diseases and Allergology, Aarhus University Hospital, Denmark b Department of Pathology, Copenhagen University Hospital, Denmark ARTICLE INFO ABSTRACT Keywords: Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare parenchymal lung disease characterized by ac- Pulmonary alveolar proteinosis cumulation of surfactant in the airways with high levels of granulocyte-macrophage colony stimulating factor Granulocyte-macrophage colony-stimulating (GM-CSF) antibodies in blood. Disease leads to hypoxemic respiratory failure. Whole lung lavage (WLL) is factor considered the first line therapy, but procedure can be quite demanding, specifically for children. Recently GM-SCF alternative treatment options with inhaled GM-CSF have been described but no consensus about the standard Molgramostim treatment exists. We here describe a unique case of a 14-year-old patient who was successfully treated with WLL Inhalation therapy and subsequent inhalations with molgramostim – new recombinant human GM-CSF (rhGM-CSF). 1. Introduction eosinophilic on hematoxylin-and eosin staining (HE) and positive with the periodic acid-Schiff stain and diastase-resistant (PAS + D), which is Pulmonary alveolar proteinosis (PAP) is a rare parenchymal lung considered characteristic for PAP (Fig. 2). Blood assays showed ele- disease characterized by accumulation of surfactant in the airways that vated high levels of GM-CSF antibodies. There was no suspicion of leads to hypoxemic respiratory failure [1–3].
    [Show full text]
  • Leukine® (Sargramostim)
    Leukine® (sargramostim) (Subcutaneous/Intravenous) Document Number: MODA-0237 Last Review Date: 04/06/2021 Date of Origin: 10/17/2008 Dates Reviewed: 06/2009, 12/2009, 06/2010, 07/2010, 09/2010, 12/2010, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 04/2019, 04/2020, 04/2021 I. Length of Authorization High Risk Neuroblastoma: − When used in combination with dinutuximab, coverage will be provided for five months and may not be renewed. − When used in combination with naxitamab, coverage will be provided for six months and may be renewed. All other indications: Coverage will be provided for four months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: − Leukine 250 mcg vial: 28 vials per 14 days − Leukine 500 mcg vial: 14 vials per 14 days B. Max Units (per dose and over time) [HCPCS Unit]: • 15 billable units per day (acute radiation syndrome) • 10 billable units per day on days 1 through 14 of cycles 1, 3 and 5 (cycle length is 24 days) for a maximum of 5 cycles only (high-risk neuroblastoma in combination with dinutuximab) • 10 billable units per day for 10 days of each 28-day cycle for six cycles followed by subsequent cycles every 8 weeks thereafter (high-risk neuroblastoma in combination with naxitamab) • 10 billable units per day (all other indications) 1-11 III.
    [Show full text]
  • Colony Stimulating Factors Medical Policy
    Medical benefit drug policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and therefore subject to change. Effective Date: 08/12/2021 Colony Stimulating Factors (CSFs) Fulphila™ (pegfilgrastim-jmbd) Granix® (tbo-filgrastim) Leukine® (sargramostim) Neulasta® (pegfilgrastim) Neulasta On-Pro® (pegfilgrastim) Neupogen® (filgrastim) Nivestym™ (filgrastim-aafi) Nyvepria™ (pegfilgrastim-apgf) Udenyca™ (pegfilgrastim-cbqv) Zarxio® (filgrastim-sndz) ZiextenzoTM (pegfilgrastim-bmez) FDA approval: Various HCPCS: Fulphila – J3490, Granix – J1447, Leukine – J2820, Neupogen – J1442, Neulasta – J2505, Nivestym J3490, Nyvepria - Q5122, Udenyca – Q5111, Zarxio – J3490, Zietxenzo – Q5120, C9058 Benefit: Both Policy: Requests must be supported by submission of chart notes and patient specific documentation. A. Coverage of the requested drug is provided for FDA approved indications and when all the following are met: a. Primary prophylaxis of chemotherapy-induced febrile neutropenia is considered clinically appropriate when ALL of the following are met: i. The individual has a non-myeloid malignancy ii. Chemotherapy intent must include one of the following: 1. Curative intent (adjuvant treatment for early stage disease, for example) OR 2. Intent is survival prolongation, and the use of a different regimen or dose reduction would reduce the likelihood of
    [Show full text]
  • WO 2018/218208 Al 29 November 2018 (29.11.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/218208 Al 29 November 2018 (29.11.2018) W !P O PCT (51) International Patent Classification: Fabio; c/o Bruin Biosciences, Inc., 10225 Barnes Canyon A61K 31/00 (2006.01) A61K 47/00 (2006.01) Road, Suite A104, San Diego, California 92121-2734 (US). BEATON, Graham; c/o Bruin Biosciences, Inc., 10225 (21) International Application Number: Barnes Canyon Road, Suite A104, San Diego, California PCT/US20 18/034744 92121-2734 (US). RAVULA, Satheesh; c/o Bruin Bio (22) International Filing Date: sciences, Inc., 10225 Barnes Canyon Road, Suite A l 04, San 25 May 2018 (25.05.2018) Diego, Kansas 92121-2734 (US). (25) Filing Language: English (74) Agent: MALLON, Joseph J.; 2040 Main Street, Four teenth Floor, Irvine, California 92614 (US). (26) Publication Langi English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/5 11,895 26 May 2017 (26.05.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/5 11,898 26 May 2017 (26.05.2017) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicants: BRUIN BIOSCIENCES, INC. [US/US]; DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 10225 Barnes Canyon Road, Suite A104, San Diego, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, California 92121-2734 (US).
    [Show full text]